Comment from Frakes Kyle

Summary: Kyle Frakes, Founder of Moonlight Longevity, strongly supports maintaining BPC-157 as an eligible compounding substance for treating ulcerative colitis and other gastrointestinal issues. He argues that the compound offers a potentially lower-risk alternative for patients who do not respond to current FDA-approved therapies.